HiberCell, Inc. has acquired the Imprime PGG program from Biothera Pharmaceuticals, Inc.
This website will deactivate on August 31. To learn more visit HiberCell.com

Biothera Pharmaceuticals to Present at the Needham & Company Healthcare Conference

EAGAN, MN — April 2, 2019 — Biothera Pharmaceuticals, Inc. today announced that Jeremy Graff, Ph.D., President and Chief Scientific Officer, and Andrew D. C. LaFrence, Senior Vice President and Chief Financial Officer, will present at the Needham & Company 18th Annual Healthcare Conference on April 9 at 3:10 PM Eastern Time in New York City.

About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held immuno-oncology company developing Imprime PGG, a novel dectin receptor agonist that reverses tumor-mediated immunosuppression while promoting antigen presentation to drive T cell activation and infiltration into tumors, and to enhance clinical benefit from immune checkpoint inhibitors.  Biothera Pharmaceuticals is currently developing this platform drug through clinical research collaborations with Merck, Genentech, Dana Farber Cancer Institute and the Big Ten Cancer Research Consortium in cancers that include triple negative breast cancer, advanced melanoma, colorectal cancer, non-small lung cell cancer.

Andrew D. C. LaFrence
SVP and Chief Financial Officer
Biothera Pharmaceuticals, Inc.



David Walsh

Leave a Reply

Your email address will not be published. Required fields are marked *